Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML

M. Terwijn; N. Feller; A. van Rhenen; A. Kelder; G.A. Westra; S. Zweegman; G.J. Ossenkoppele; G.J. Schuurhuis

doi:10.1016/j.ejca.2009.02.021

Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML

M. Terwijn, N. Feller, A. van Rhenen, A. Kelder, G.A. Westra, S. Zweegman, G.J. Ossenkoppele, G.J. Schuurhuis

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

We investigated the role of CD25 as a prognostic marker in acute myeloid leukaemia (AML). Seventy-two newly diagnosed patients ≤60 years were retrospectively analysed by flow cytometry for CD25 positivity of AML blasts. Patients with CD25 expression of >10%, when compared to ≤10%, had a significantly shorter overall survival (OS, p = 0.0005) and relapse-free survival (RFS, p = 0.005). In multivariate analysis CD25 expression is an independent adverse factor for OS and RFS. High CD25 combined with FLT3-ITD positivity resulted in the poorest OS and RFS (p = 0.001 and p = 0.003, respectively). CD25 expression remained prognostic within the intermediate cytogenetic risk group. In addition, after the first cycle of chemotherapy, a significantly higher MRD frequency was found in patients expressing CD25 above cut-off (p = 0.003). Our results show that CD25 expression is an independent adverse prognostic marker in AML patients ≤60 and correlates with MRD. © 2009 Elsevier Ltd. All rights reserved.

Original language	English
Pages (from-to)	1692-1699
Number of pages	8
Journal	European Journal of Cancer
Volume	45
Issue number	9
DOIs	https://doi.org/10.1016/j.ejca.2009.02.021
Publication status	Published - Jun 2009

Access to Document

10.1016/j.ejca.2009.02.021

http://www.mendeley.com/research/interleukin2-receptor-alphachain-cd25-expression-leukaemic-blasts-predictive-outcome-level-residual-1

Cite this

Terwijn, M., Feller, N., van Rhenen, A., Kelder, A., Westra, G. A., Zweegman, S., ... Schuurhuis, G. J. (2009). Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML. European Journal of Cancer, 45(9), 1692-1699. https://doi.org/10.1016/j.ejca.2009.02.021

@article{67c5591d929b4007bf9d26def1994bc1,

title = "Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML",

abstract = "We investigated the role of CD25 as a prognostic marker in acute myeloid leukaemia (AML). Seventy-two newly diagnosed patients ≤60 years were retrospectively analysed by flow cytometry for CD25 positivity of AML blasts. Patients with CD25 expression of >10{\%}, when compared to ≤10{\%}, had a significantly shorter overall survival (OS, p = 0.0005) and relapse-free survival (RFS, p = 0.005). In multivariate analysis CD25 expression is an independent adverse factor for OS and RFS. High CD25 combined with FLT3-ITD positivity resulted in the poorest OS and RFS (p = 0.001 and p = 0.003, respectively). CD25 expression remained prognostic within the intermediate cytogenetic risk group. In addition, after the first cycle of chemotherapy, a significantly higher MRD frequency was found in patients expressing CD25 above cut-off (p = 0.003). Our results show that CD25 expression is an independent adverse prognostic marker in AML patients ≤60 and correlates with MRD. {\circledC} 2009 Elsevier Ltd. All rights reserved.",

keywords = "Acute myeloid leukaemia, Flow cytometry, IL-2 receptor, Intermediate cytogenetics, Prognosis",

author = "M. Terwijn and N. Feller and {van Rhenen}, A. and A. Kelder and G.A. Westra and S. Zweegman and G.J. Ossenkoppele and G.J. Schuurhuis",

year = "2009",

month = "6",

doi = "10.1016/j.ejca.2009.02.021",

language = "English",

volume = "45",

pages = "1692--1699",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Pergamon",

number = "9",

}

Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML. / Terwijn, M.; Feller, N.; van Rhenen, A.; Kelder, A.; Westra, G.A.; Zweegman, S.; Ossenkoppele, G.J.; Schuurhuis, G.J.

In: European Journal of Cancer, Vol. 45, No. 9, 06.2009, p. 1692-1699.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML

AU - Terwijn, M.

AU - Feller, N.

AU - van Rhenen, A.

AU - Kelder, A.

AU - Westra, G.A.

AU - Zweegman, S.

AU - Ossenkoppele, G.J.

AU - Schuurhuis, G.J.

PY - 2009/6

Y1 - 2009/6

N2 - We investigated the role of CD25 as a prognostic marker in acute myeloid leukaemia (AML). Seventy-two newly diagnosed patients ≤60 years were retrospectively analysed by flow cytometry for CD25 positivity of AML blasts. Patients with CD25 expression of >10%, when compared to ≤10%, had a significantly shorter overall survival (OS, p = 0.0005) and relapse-free survival (RFS, p = 0.005). In multivariate analysis CD25 expression is an independent adverse factor for OS and RFS. High CD25 combined with FLT3-ITD positivity resulted in the poorest OS and RFS (p = 0.001 and p = 0.003, respectively). CD25 expression remained prognostic within the intermediate cytogenetic risk group. In addition, after the first cycle of chemotherapy, a significantly higher MRD frequency was found in patients expressing CD25 above cut-off (p = 0.003). Our results show that CD25 expression is an independent adverse prognostic marker in AML patients ≤60 and correlates with MRD. © 2009 Elsevier Ltd. All rights reserved.

AB - We investigated the role of CD25 as a prognostic marker in acute myeloid leukaemia (AML). Seventy-two newly diagnosed patients ≤60 years were retrospectively analysed by flow cytometry for CD25 positivity of AML blasts. Patients with CD25 expression of >10%, when compared to ≤10%, had a significantly shorter overall survival (OS, p = 0.0005) and relapse-free survival (RFS, p = 0.005). In multivariate analysis CD25 expression is an independent adverse factor for OS and RFS. High CD25 combined with FLT3-ITD positivity resulted in the poorest OS and RFS (p = 0.001 and p = 0.003, respectively). CD25 expression remained prognostic within the intermediate cytogenetic risk group. In addition, after the first cycle of chemotherapy, a significantly higher MRD frequency was found in patients expressing CD25 above cut-off (p = 0.003). Our results show that CD25 expression is an independent adverse prognostic marker in AML patients ≤60 and correlates with MRD. © 2009 Elsevier Ltd. All rights reserved.

KW - Acute myeloid leukaemia

KW - Flow cytometry

KW - IL-2 receptor

KW - Intermediate cytogenetics

KW - Prognosis

U2 - 10.1016/j.ejca.2009.02.021

DO - 10.1016/j.ejca.2009.02.021

M3 - Article

C2 - 19321337

VL - 45

SP - 1692

EP - 1699

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 9

ER -